ISPC - iSpecimen Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Lexington,
United States
Type: Equity
ISPC price evolution
ISPC
| (in millions $) | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.15 | $2.09 | $2.34 | $2.72 |
| Short term investments | ||||
| Net receivables | $2.85 | $2.42 | $2.94 | $3.14 |
| Inventory | ||||
| Total current assets | $5.24 | $5.29 | $8.24 | $9.13 |
| Long term investments | ||||
| Property, plant & equipment | $0.13 | $0.27 | $0.32 | $0.38 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $11.9 | $12.51 | $15.82 | $16.3 |
| Current liabilities | ||||
| Accounts payable | $4.21 | $3.56 | $3.93 | $2.28 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5.81 | $5.7 | $6.05 | $3.52 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $5.81 | $5.7 | $6.08 | $3.59 |
| Shareholders' equity | ||||
| Retained earnings | -$64.38 | -$62.27 | -$59.36 | -$56.29 |
| Other shareholder equity | $0 | $0 | $0 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.34 | $15.31 | $27.74 | $0.7 |
| Short term investments | ||||
| Net receivables | $2.94 | $4.07 | $4.88 | $2.36 |
| Inventory | ||||
| Total current assets | $8.24 | $19.68 | $32.95 | $3.47 |
| Long term investments | ||||
| Property, plant & equipment | $0.32 | $0.41 | $0.03 | $0.08 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $2.74 | |||
| Total investments | ||||
| Total assets | $15.82 | $24.62 | $35.72 | $6.21 |
| Current liabilities | ||||
| Accounts payable | $3.93 | $2.46 | $0.83 | $1.79 |
| Deferred revenue | $0.87 | |||
| Short long term debt | ||||
| Total current liabilities | $6.05 | $4.28 | $2.51 | $22.14 |
| Long term debt | $3.42 | $0.18 | ||
| Total noncurrent liabilities | $0.18 | |||
| Total debt | ||||
| Total liabilities | $6.08 | $4.31 | $5.93 | $22.31 |
| Shareholders' equity | ||||
| Retained earnings | -$59.36 | -$48.27 | -$38.02 | -$29.06 |
| Other shareholder equity | $0 | $11.17 | ||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.34 | $2.52 | ||
| Cost of revenue | ||||
| Gross Profit | $1.34 | $1.35 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $3.92 | $3.71 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.03 | -$0.03 | ||
| Net income | ||||
| Net income | -$2.61 | -$2.38 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $11.14 | $8.18 | $4.3 | $4.39 |
| Cost of revenue | ||||
| Gross Profit | $5.89 | $4.6 | $2.17 | $2.03 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $11.81 | $7.59 | $6.18 | $5.39 |
| Operating income | -$2.41 | -$3.88 | ||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.16 | -$0.13 | ||
| Interest expense | -$0.78 | $2.1 | $1.72 | -$2.16 |
| Net income | ||||
| Net income | -$8.96 | -$4.65 | -$4.73 | -$5.35 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$1.55 | -$0.78 | -$0.34 | -$1.04 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.08 | $0.08 | $0.08 | $38.75 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$7.08 | -$4.05 | -$1.64 | $27.04 |
| (in millions $) | 31 Jan 2022 | 31 Jan 2021 | 31 Jan 2020 | 31 Jan 2019 |
|---|---|---|---|---|
| Net income | -$4.65 | -$4.73 | ||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$0.29 | -$2.68 | ||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$1.04 | -$1.1 | -$1.48 | -$1.03 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $38.75 | $2.03 | $3.08 | $3.52 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $27.04 | $0.64 | -$1.08 | -$0.19 |
News
Fundamentals
| Market cap | $59.98M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 13.10M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.16 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.90 |
| Quick ratio | N/A |